Table 1.
Cixutumumab Gemcitabine + Erlotinib |
Gemcitabine + Erlotinib | |
---|---|---|
N | 57 | 59 |
Median age | 63 | 64 |
Females | 60% | 41% |
ECOG PS 0/1 (%) | 40/60 | 45/55 |
Liver metastases (%) | 80% | 68% |
Prior radical pancreatic surgery | 14% | 12% |
Pre-existing diabetes mellitus | 25% | 32% |